LSCD101(LSCD101) - _专利_临床

概要

基本信息

药物类型

生物药

别名

Autologous Limbal Epithelial Cell Transplantation

靶点-

作用方式-

作用机制-

治疗领域

眼部疾病其他疾病

在研适应症-

非在研适应症

老年环边缘干细胞缺乏症

原研机构

CLIPS SA

在研机构-

非在研机构

CLIPS SA

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 LSCD101 相关的临床试验

KCT0010067

/ Not yet recruiting临床2期IIT

Single-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

开始日期2025-01-09

申办/合作机构-

KCT0004741

/ Completed临床1期

Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

开始日期2020-01-31

申办/合作机构

CLIPS SA

NCT04773431

/ Completed临床1期

Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

Clinical Study Objective:
To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency
Study Method:
Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

开始日期2020-01-31

申办/合作机构

CLIPS SA

100 项与 LSCD101 相关的临床结果

登录后查看更多信息

100 项与 LSCD101 相关的转化医学

登录后查看更多信息

100 项与 LSCD101 相关的专利（医药）

登录后查看更多信息

100 项与 LSCD101 相关的药物交易

登录后查看更多信息